Company intelligence / Profile preview

IVIEW Therapeutics Inc.

Cranbury, New Jersey, United Statesiviewtherapeutics.com ↗

Ownership: Private
Employees: ~11
Development stage: Phase 2

Overview

Positive topline results from Phase 1/2 trial of IVW-1001 ophthalmic eyelid wipe for dry eye disease reported in February 2025. The treatment was well-tolerated with no serious adverse events related to the investigational product. The trial enrolled 150 patients across 10 sites in the United States.[6]

Therapeutic areas: OphthalmologyPulmonology
Modalities: Small moleculesGene therapyExtended-release formulationsCombination therapies
Industry: Biotech

Drug pipeline

9 assets

IVW-1001

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on IVIEW Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVIEW Therapeutics Inc..

Explore the full profile